Publications by authors named "H Hanabusa"

Claim this Profile
L
Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors.
Midori Shima, Hideji Hanabusa, Masashi Taki, Tadashi Matsushita, Tetsuji Sato

Blood Adv· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
Sandrine Meunier, Jayanthi Alamelu, Silke Ehrenforth, Hideji Hanabusa, Faraizah Abdul Karim

Thromb Haemost· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brief Report: The Impact of Ledipasvir/Sofosbuvir on HIV-Positive and HIV-Negative Japanese Hemophilia Patients With 1, 4, and Mixed-Genotype HCV.
Azusa Nagao, Hideji Hanabusa

J Acquir Immune Defic Syndr· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of the Japanese subgroup in LEOPOLD II: a phase 2/3 study of BAY 81-8973, a new recombinant factor VIII product.
Teruhisa Fujii, Hideji Hanabusa, Midori Shima, Takeshi Morinaga, Katsuyuki Fukutake

Int J Hematol· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
Paul Giangrande, Tatiana Andreeva, Pratima Chowdary, Silke Ehrenforth, Hideji Hanabusa

Thromb Haemost· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis